Return to the full list of Biomarkers
APP 669–711/Aβ 1–42
Method of Measurement (Pre-analytical Tools)
Blood/Plasma
Biomarker Measured
Amyloid
Use
Prognostic
Stage of Development
Preclinical
Active vs Completed Trials
Completed
Aim/Results
Blood ratios of amyloid-β precursor protein (APP)669–711 to amyloid-β (Aβ)1–42 showed high performance when predicting brain amyloid-β burden.
What is Required from Patients
blood draw, mild discomfort, in clinic visits
What is Required from the Health System
phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, or western blot)
-
“Closing in on a Blood Test for Alzheimer’s?” Alzforum. https://www.alzforum.org/news/research-news/closing-blood-test-alzheimers
-
Kaneko, N., Nakamura, A., Washimi, Y., Kato, T., Sakurai, T., Arahata, Y., ... & Toba, K. (2014). Novel plasma biomarker surrogating cerebral amyloid deposition. Proceedings of the Japan Academy, Series B, 90(9), 353-364. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324927/
- Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., ... & Tomita, T. (2018). High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature, 554(7691), 249. https://www.ncbi.nlm.nih.gov/pubmed/29420472